Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: AAB-003 (PF-05236812)

First Posted Date: 2011-06-08

Last Posted Date: 2017-03-10

Lead Sponsor: Pfizer

Target Recruit Count: 52

Registration Number: NCT01369225

Locations: 🇺🇸
Borgess Research Institute, Kalamazoo, Michigan, United States
🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸
Munroe Regional Medical Center, Ocala, Florida, United States

and more 18 locations

A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532

Phase 1

Completed

Conditions: Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders

Interventions: Drug: PF-04991532
Drug: Placebo

First Posted Date: 2011-06-08

Last Posted Date: 2011-09-22

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT01369277

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Completed

Conditions: Lymphoma, Mantle-Cell
Carcinoma, Renal Cell

Interventions: Other: Temsirolimus (Non-Interventional Study)

First Posted Date: 2011-06-07

Last Posted Date: 2016-04-27

Lead Sponsor: Pfizer

Target Recruit Count: 243

Registration Number: NCT01367457

Locations: 🇪🇸
Hospital Provincial de Castellon, Castellon, Valencia, Spain
🇪🇸
Complejo Hospitalario Materno-Infantil Insular de Las Palmas, Las Palmas de Gran Canaria, Las Palmas, Spain
🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

and more 13 locations

A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-03882845

First Posted Date: 2011-06-06

Last Posted Date: 2011-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01366287

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

Phase 1

Completed

Conditions: Pain

Interventions: Drug: PF-05089771

First Posted Date: 2011-06-03

Last Posted Date: 2011-10-06

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT01365637

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: ARRY-371797, p38 inhibitor; oral
Drug: Placebo; oral
Drug: Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral

First Posted Date: 2011-06-03

Last Posted Date: 2020-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 157

Registration Number: NCT01366014

Locations: 🇺🇸
Pfizer Investigational Site, Kenosha, Wisconsin, United States

A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone Propionate
Drug: Placebo for Fluticasone Propionate

First Posted Date: 2011-06-02

Last Posted Date: 2012-02-13

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT01364519

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Phase 1

Completed

Conditions: Staphylococcal Infections

Interventions: Biological: SA4Ag vaccine low dose
Biological: SA4Ag vaccine mid dose
Biological: SA4Ag vaccine high dose
Biological: Placebo
Procedure: Blood draw
Procedure: Blood sample
Procedure: Colonization swab sample

First Posted Date: 2011-06-02

Last Posted Date: 2019-03-04

Lead Sponsor: Pfizer

Target Recruit Count: 456

Registration Number: NCT01364571

Locations: 🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸
Buffalo Clinical Research Center, LLC, Buffalo, New York, United States
🇺🇸
PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States

and more 12 locations

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Acute Lymphocytic Leukemia

Interventions: Drug: Inotuzumab Ozogamicin

First Posted Date: 2011-06-01

Last Posted Date: 2017-04-13

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT01363297

Locations: 🇺🇸
Stanford Unversity Cancer Clinical Trials Office, Palo Alto, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Stanford Unversity Hospital and Clinics, CTRU, Palo Alto, California, United States

and more 12 locations

Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients

Completed

Conditions: Complicated Skin and Structure Infection
Nosocomial Pneumonia

Interventions: Drug: Linezolid
Drug: Vancomycin

First Posted Date: 2011-06-01

Last Posted Date: 2012-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 7260

Registration Number: NCT01363271

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy